Cargando…

PB2476: TARGETING OF BRD4 TO COUNTERACT CYTOKINE-INDUCED EXPRESSION OF PD-L1 AND PD-L2 ON VASCULAR, OSTEOBLASTIC AND STROMAL NICHE CELLS

Detalles Bibliográficos
Autores principales:	Filik, Yüksel, Bauer, Karin, Valent, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429155/ http://dx.doi.org/10.1097/01.HS9.0000976608.93262.7f

Ejemplares similares

PB1919: S100A9 DEFICIENCY ACCELERATES MDS ASSOCIATED TUMOR ESCAPE VIA PD-1/PD-L1 OVEREXPRESSION
por: Wang, R., et al.
Publicado: (2022)

PB2344: STR-LOCI ALLELE IMBALANCE AT 9P24.1 AND PD-L1 EXPRESSION IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA.
por: Abdurashidova, Runiza, et al.
Publicado: (2023)

PB2520: NEWBORN SCREENING PROGRAM IN SAUDI ARABIA FOR EARLY DETECTION OF HEMOGLOBINOPATHIES AND G6PD
por: Ezzat, Hatoon, et al.
Publicado: (2023)

PB2259: THE NEW PD-1 INHIBITOR PROLGOLIMAB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA
por: Semenova, Anastasia, et al.
Publicado: (2023)

PB1966: HEMOPOIETIC NICHE IMPAIRMENT IN TREATED MULTIPLE MYELOMA PATIENTS
por: Semenova, N. Y., et al.
Publicado: (2022)

PB2261: DECREASE IN NEUTROPHIL-LYMPHOCYTE RATIO IMPACTS OVERALL SURVIVAL OF ADULT PATIENTS WITH HODGKIN LYMPHOMA AFTER ANTI-PD1 TREATMENT
por: Varelas, Christos, et al.
Publicado: (2023)

PB2200: FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS
por: Allard, Martine, et al.
Publicado: (2023)

Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia
por: Chen, Cunte, et al.
Publicado: (2021)

PB2447: PREEMPTIVE TREATMENT WITH PD-1 ANTIBODY FOR ACUTE MYELOID LEUKEMIA/MYELODYSPLASTIC SYNDROME WITH POSITIVE MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: MA, Ling, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells
por: Kim, Su-Lim, et al.
Publicado: (2023)

PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL
por: Shortt, Jake, et al.
Publicado: (2023)

PB2172: PREVALENCE OF FIP1L1-PDGFRΑ FUSION IN TUNISIAN PATIENTS WITH HYPEREOSINOPHILIA
por: Torkhani, Nermine, et al.
Publicado: (2023)

IFN-γ induces PD-L1 through p38/JNK/ERK signaling pathways and counteracts the tumor promoting effect mediated by PD-L1 in Glioblastoma
por: Jia, Huafang, et al.
Publicado: (2022)

PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
por: Innocenti, Idanna, et al.
Publicado: (2023)

Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells
por: Ebine, Kazumi, et al.
Publicado: (2018)

Immunomodulatory Effect and Bone Homeostasis Regulation in Osteoblasts Differentiated from hADMSCs via the PD-1/PD-L1 Axis
por: Lee, Seung-Cheol, et al.
Publicado: (2022)

PB1818: PROGNOSTIC VALUE OF NEOPLASTIC INFLAMMATION AND CYTOKINES IN THE COURSE OF ACUTE MYELOID LEUKEMIA WITH MATURATION
por: Barilka, Vira, et al.
Publicado: (2023)

PB2403: THE FREQUENCY OF L265P MUTATION IN MYD88 GENE AT DIFFUSE LARGE B-CELL LYMPHOMA
por: Dubrovina, Anastasiya, et al.
Publicado: (2023)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

PB1967: ROLE OF CYTOKINES IN MULTIPLE MYELOMA: IL-1RN AND IL-4 VNTR POLYMORPHISMS
por: Serin, I., et al.
Publicado: (2022)

PB1830: THE PROGNOSTIC AND PATHOGENETIC SIGNIFICANCE OF СOMPONENTS OF NEOPLASTIC INFLAMMATION AND CYTOKINES IN THE ADULT WITH ACUTE LEUKEMIA
por: Barilka, Vira, et al.
Publicado: (2023)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

PB1795: MESENCHYMAL STROMAL CELL-DEPENDENT ADHESION PATHWAYS PROTECT AML CELLS FROM VENETOCLAX-INDUCED APOPTOSIS
por: Ciciarello, Marilena, et al.
Publicado: (2023)

Draft Genome Sequence of Lactobacillus pasteurii CRBIP 24.76(T)
por: Cousin, Sylvie, et al.
Publicado: (2013)

2476. Impact of the Vaccination Strategy on Varicella Burden Disease in Argentina
por: Neyro, Silvina, et al.
Publicado: (2018)

2476: Identifying strangulated small bowel obstruction with machine learning
por: David Zetumer, Samuel, et al.
Publicado: (2018)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

PB2389: DIAGNOSTIC SIGNIFICANCE OF CYTOKINE EXPRESSION LEVELS IN CEREBROSPINAL FLUID FOR CENTRAL NERVOUS SYSTEM INFILTRATION OF LYMPHOMA
por: Xin, Luo, et al.
Publicado: (2023)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
por: Spirina, Liudmila, et al.
Publicado: (2021)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2022)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h13m6s660o0t3ccir77osppjlm